969
Views
12
CrossRef citations to date
0
Altmetric
Research Paper

Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine

, , , , &
Pages 478-484 | Received 13 May 2015, Accepted 22 Jul 2015, Published online: 23 Feb 2016

References

  • Neuzil KM, Coffey CS, Mitchel EF, Jr., Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003; 34:304-7; PMID:14600576; http://dx.doi.org/10.1097/00126334-200311010-00008
  • Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-6; PMID:11176770; http://dx.doi.org/10.1001/archinte.161.3.441
  • Pinto LA, Blazevic V, Anderson SA, Venzon DJ, Trubey CM, Rowe T, Katz JM, Liewehr D, Dolan MJ, Shearer GM. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis 2001; 183:1000-8; PMID:11237823; http://dx.doi.org/10.1086/319277
  • Santini-Oliveira M, Camacho LA, Souza TM, Luz PM, Vasconcellos MT, Giacoia-Gripp CB, Morgado MG, Nunes EP, Lemos AS, Ferreira AC, et al. H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PloS one 2012; 7:e39310; PMID:22761759; http://dx.doi.org/10.1371/journal.pone.0039310.
  • Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46; PMID:21148532; http://dx.doi.org/10.1093/cid/ciq019.
  • Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83; http://dx.doi.org/10.1001/jama.1989.03430060075029.
  • Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109:383-8; PMID:2970238; http://dx.doi.org/10.7326/0003-4819-109-5-383.
  • Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, Kottilil S, Gezmu M, Follmann D, Vodeiko GM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442-50; PMID:15809902; http://dx.doi.org/10.1086/429298.
  • Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-40; PMID:17578785; http://dx.doi.org/10.1086/518986.
  • Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29:8788-801; PMID:21968444; http://dx.doi.org/10.1016/j.vaccine.2011.09.077.
  • Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301; PMID:15525714; http://dx.doi.org/10.1056/NEJMoa043540.
  • Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253-9; PMID:18003811; http://dx.doi.org/10.1128/CVI.00316-07.
  • Gabutti G, Guido M, Durando P, De Donno A, Quattrocchi M, Bacilieri S, Ansaldi F, Cataldini S, Chiriac∫ PG, De Simone M, et al. Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients. J Int Med Res 2005; 33:406-16; PMID:16104444; http://dx.doi.org/10.1177/147323000503300406.
  • McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, DiGiorgio C, Kenney T, Boyer J, Tebas P. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013; 158:19-26; PMID:23277897; http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00005.
  • Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PloS One 2011; 6:e17758; PMID:21512577; http://dx.doi.org/10.1371/journal.pone.0017758.
  • Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-78; PMID:21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007.
  • Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. Hum Vaccin Immunother 2012; 8:1048-52; PMID:22832261; http://dx.doi.org/10.4161/hv.20347.
  • Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults. J Infect Dis 2015; 211:1969-76; PMID:25567841; http://dx.doi.org/10.1093/infdis/jiu841.
  • Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-37; PMID:21148531; http://dx.doi.org/10.1093/cid/ciq004.
  • Schneider MM, Sprenger MJ, Hoepelman IM, van der Graaf Y, Borleffs JC. Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1. Int J Antimicrob Agents 1996; 6:195-200; PMID:18611709; http://dx.doi.org/10.1016/0924-8579(95)00038-0.
  • Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. Aids 1994; 8:469-76; PMID:7912086; http://dx.doi.org/10.1097/00002030-199404000-00008.
  • Cooper CL. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis 2012; 25:26-35; PMID:22183114; http://dx.doi.org/10.1097/QCO.0b013e32834ef56c.
  • Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-9; PMID:10825608; http://dx.doi.org/10.1016/S0264-410X(00)00079-7.
  • Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 2012; 19:897-908; PMID:22492743; http://dx.doi.org/10.1128/CVI.05726-11.
  • Cheong HJ, Song JY, Park JW, Yeon JE, Byun KS, Lee CH, Cho HI, Kim TG, Kim WJ. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 2006; 24:2417-22; PMID:16406176; http://dx.doi.org/10.1016/j.vaccine.2005.11.064.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.